@daltonventure
以生命科学为根，向硬科技生长
From science fiction to reality, brain-computer interfaces are drawing closer. As humans gain the ability to read, understand, and even intervene in the brain, a new question emerges: where exactly will brain-computer technology take us?
Brain signals are controlling robotic arms, ultrasound is being used to probe the brain, and flexible neural electrodes are inching closer to real clinical applications...
Recently, **Astribot — a Dalton Venture portfolio company and the world's first company to mass-produce cable-driven AI robots — has completed a new funding round of approximately one billion yuan. The company is now valued at 15 billion yuan, firmly securing its place in the top tier of China's Embodied Artificial Intelligence companies.** This round was led by Shenzhen Investment Holdings Donghai (a subsidiary of Shenzhen Investment Holdings), with participation from Hongtai APlus, Ninghai Xingtaihe Fund managed by Guanghua Yangguang, Shanheng Capital, and other key state-owned and financial investors, as well as existing shareholder Xianmu...
Recently, a Dalton Venture portfolio company — **Hangzhou Xizi Shenghe Technology Co., Ltd.** — received exclusive strategic investment from Henan HuiRong Fund and established a strategic partnership with the biomanufacturing pilot base under Henan Investment Group.
On October 9, 2026, **Dalton Venture portfolio company Triastek (Nanjing) Pharmaceutical Technology Co., Ltd.** (hereinafter referred to as "Triastek" or "the Company") announced that **the Company and its wholly-owned subsidiary Triastek (Shanghai) Pharmaceutical Technology Co., Ltd. have entered into a collaboration and license agreement with Johnson & Johnson**. The two parties will combine Johnson & Johnson's expertise in pharmaceutical development with Triastek's
Recently, Cyzone released its "**Most Admired Venture Capital Firms 2026**" rankings. **Dalton Venture** was selected for the "**Top 50 Most Admired Early-Stage Investment Firms 2026**" and also made the vertical-sector list "**Top 30 Bio/Medical Technology**."
On September 21, the report *AI Virtual Cell (AIVC): Technology Trends, Industrial Ecosystem, and Application Prospects — New Infrastructure for Life Sciences in the AI Era* was officially released. Initiated by **Baiyao Technology**, a **Dalton Venture family company**, the report was researched and written by the *MIT Technology Review* China team, and completed under the guidance of the Beijing Zhongguancun Science City Innovation Development. The report takes a global perspective, drawing on research from dozens of scientific institutions worldwide.
On September 13, the **Synthetic Biology Innovation Forum, part of the 2026 Pujiang Innovation Forum, was held in Shanghai, with Yaochao Chen, Managing Director of Dalton Venture and head of its Hong Kong fund, invited to attend.** The forum was hosted by the Ministry of Science and Technology of the People's Republic of China and the Shanghai Municipal People's Government, and organized by the Shanghai Synthetic Biology Innovation Center. It is one of the key thematic forums of the 2026 Pujiang Innovation Forum, bringing together participants from multiple countries including China, the United States, Denmark, Germany, and Switzerland.
Recently, **Zhejiang Weibang Zhendian Optoelectronic Technology Co., Ltd. (hereinafter: Weibang Zhendian) completed a nearly RMB 100 million Series B round, led by Dalton Venture with participation from IDG Capital**. The funds will primarily be used to advance the commercialization of its products in industrial inspection, clinical applications, AI for Science, and other fields. Prior to this, Weibang Zhendian had completed two funding rounds, with investors including Tao Capital, FreeS Fund, Founder Hesheng, Naton Capital, and SND Group.
Recently, the winners of three major rankings were announced: the 10th Healthcare Investment Excellence Awards, the **Touzijia** 2025–2026 Fund Partner Rankings, and the Qimingpian 2026 Mid-Year China Equity Investment Rankings. Across the three lists, **Ning Huang, founding partner of Dalton Venture, was named to the Best Early-Stage Investor TOP 25, while Dalton Venture was recognized as Best Biotech Investment Firm, Best AI Healthcare Breakthrough Investment Firm, Best Innovative Medical Devices and Life Sciences Investment Firm, and...
